HemaSense

Linkedin

Early Bleed Detection, Accelerated Recovery

HemaSense is Improving patient outcomes and reducing costs of percutaneous interventions by providing healthcare professionals the first early alert system for bleeding complications at the access site during post-op recovery.

Clinical Need

Over 46 million percutaneous endovascular interventional procedures were performed worldwide in 2023, with an expected CAGR of 5-7%.

LEARN MORE

Approximately 5% of those endovascular procedures result in painful and costly access site bleeding complications.

LEARN MORE

When a clinically significant bleeding complication occurs, patients experience longer hospital stays, secondary procedures and increased mortality and morbidity.

LEARN MORE

The Solution

HemaSense is developing an access site monitor which is used during patient recovery to provide early detection and alert of subcutaneous bleeding events.

The HemaSense monitor seamlessly integrates with existing patient recovery workflow and enables early, less costly interventions for patients when small amounts of blood are beginning to accumulate outside the femoral vessel.

Illustrations are conceptual and do not depict the final product. This medical device is under development and not yet approved by any regulatory agency.

Our Team

The HemaSense team has decades of experience in medical device design and development, and a deep clinical background in percutaneous interventions. 

Closeup Headshot
Nathan has over 20 years in Medtech Innovation resulting in several successful device development and commercialization efforts. His degree in Mechanical and Materials Engineering from RPI is complemented by leadership positions in new market discovery and business development during his 19 years at WL Gore and Associates. Nathan has supported multiple M&A efforts and also successfully founded, grew, and sold a company in the beverage industry.
Nathan Friedman
CEO, Co-Founder
NZ6_0504
Ben has over 26 years of experience designing and developing medical devices for a variety of applications. He has a BS in Materials Science from Drexel University and spent 24 years at WL Gore and Associates. He utilizes a deep materials and mechanical engineering background and a skillset in marrying novel technologies with customer needs to solve complex clinical problems. Ben has over 25 issued patents, and has held multiple technical and leadership roles.
Ben Trapp
CTO, Co-Founder
Anita Headshot
Dr. Anita Asgar is an Interventional Cardiologist and Medical Director of the Structural Heart Program at the Montreal Heart Institute. She has extensive expertise in transcatheter valve interventions, congenital interventions and cardiac MRI. Dr. Asgar has chaired multiple committees and edited 2 E-books in the Transcatheter Valve space. She will join Northwestern Medicine in 2025 as Section Chief of Interventional Cardiology and System Medical Director of Structural Interventions.
Anita Asgar, MD
CMO, Co-Founder
cody_headshot
Cody is a seasoned innovator with 23 years of experience in the medical device industry. Driven by a passion for improving patient outcomes, he specializes in bringing disruptive technologies to market. Cody's expertise includes prototyping, testing, failure analysis, and computational structural and fluid mechanics. He holds a Bachelor's degree in Aerospace Engineering from the University of Arizona and has 45 issued U.S. patents on novel implantable materials and medical device technologies.
Cody Hartman
Advisor, Co-Founder

Contact Us

HemaSense is currently completing our technology development and are actively seeking partners for our next phase of product development.  

If you are a like-minded individual with a passion for accelerating patient recovery, please reach out to us.  We are currently seeking specific expertise in electrical engineering and programming, as well as investors for our pre-seed funding round. 

Drop us a note, we would love to hear from you!

Please enable JavaScript in your browser to complete this form.
Name